Chronic Lymphoid Leukemia in Relapse research hub

Belimumab in Patients with Chronic Lymphocytic Leukemia

This study looks at adding a new drug, belimumab, to standard treatment (rituximab/venetoclax) for chronic lymphocytic leukemia (CLL) that has come back or isn't responding. The aim is to make the treatment work better and potentially reduce its overall length.